FindTrial
Sign In

A phase III clinical study of HFT-290.

A phase III clinical study of HFT-290 in patients with cancer pain.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080223308
Enrollment
Unknown
Registered
2016-09-01
Start date
2016-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

investigational material(s) Generic name etc : HFT-290(fentanyl citrate patch) INN of investigational material : fentanyl citrate Therapeutic category code : 821 Synthetic narcotics Dosage and Adminis

Sponsors

Hisamitsu Pharmaceutical Co.,Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients with a diagnosis of cancer who are informed about their disease.

Exclusion criteria

Exclusion criteria: - Patients with abnormalities at the target application site. - Patients with serious cardiac, hepatic, or renal dysfunction, serious respiratory disease, or serious respiratory depression.

Design outcomes

Primary

MeasureTime frame
Efficacy, and safety.—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026